RxDoctor Payments Data

Celia Herring

Family · Sumter, SCNPI 1821258435

Payments from drug & device makers

$6,162in general payments, 2019–2025

Across 304 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$946
  • Lilly USA, LLC$578
  • Novo Nordisk$488
  • Abbott$468
  • AstraZeneca$408
  • Bayer$312
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,162100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,162 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$30,244
Medicare patients
148
Services billed
974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$143,268
JardianceEmpagliflozin116$129,264
MounjaroTirzepatide93$120,356
TrulicityDulaglutide52$81,671
FarxigaDapagliflozin Propanediol62$57,582
EliquisApixaban55$50,553
LinzessLinaclotide45$45,144
JanuviaSitagliptin Phosphate33$33,935
RybelsusSemaglutide26$32,067
VraylarCariprazine Hcl15$23,131
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,632
Tresiba Flextouch U-100Insulin Degludec26$12,173
Novolog FlexpenInsulin Aspart43$11,673
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$8,687
Humalog Kwikpen U-100Insulin Lispro22$7,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$578$202,027145 claims
Novo NordiskOzempic, Rybelsus$488$175,336132 claims
Boehringer IngelheimJardiance$156$129,264116 claims
AbbVieLinzess, Vraylar$285$68,27560 claims
AstraZenecaFarxiga$408$57,58262 claims
PfizerEliquis$137$50,55355 claims
MerckJanuvia$80$33,93533 claims
GSKTrelegy Ellipta, Breo Ellipta$151$20,90432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Sumter

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →